Filing Flows › Comparisons › RGNX vs CCCC
Regenxbio vs C4 Therapeutics: RGNX and CCCC compared
Regenxbio is the larger company: $9.2M of revenue in its latest quarter (Q3 2026) against $8.5M for C4 Therapeutics (Q3 2026). C4 Therapeutics is growing faster (-25% against -69% a year earlier). C4 Therapeutics is more profitable, with an operating margin of -290.5% against -387.8%.
Where the money goes: RGNX and CCCC
Regenxbio (RGNX) · Q3 2026
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
C4 Therapeutics (CCCC) · Q3 2026
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
| Regenxbio (RGNX) | C4 Therapeutics (CCCC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $9.2M | $8.5M |
| Revenue growth, Y/Y | -69% | -25% |
| Operating margin | -387.8% | -290.5% |
| Net earnings | −$40.7M | −$21.8M |
| Net margin | -444.6% | -257.9% |
| Operating cash flow | $38.6M | −$26.0M |
| Free cash flow | $38.4M | — |
Where the revenue comes from
Regenxbio
- License and Service: $5.2M (57%)
- Service: $3.9M (43%)
Questions
Which is bigger, Regenxbio or C4 Therapeutics?
Regenxbio is the larger company: $9.2M of revenue in its latest quarter (Q3 2026) against $8.5M for C4 Therapeutics (Q3 2026).
Is Regenxbio or C4 Therapeutics growing faster?
C4 Therapeutics is growing faster (-25% against -69% a year earlier).
Which is more profitable, Regenxbio or C4 Therapeutics?
C4 Therapeutics is more profitable, with an operating margin of -290.5% against -387.8%.
More: Regenxbio earnings · how Regenxbio makes money · C4 Therapeutics earnings · how C4 Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.